- Home
- TOPP vs AKTX Comparison
TOPP vs AKTX Comparison
Compare TOPP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- AKTX
- Stock Information
- Founded
- TOPP 2014
- AKTX N/A
- Country
- TOPP United States
- AKTX United States
- Employees
- TOPP N/A
- AKTX N/A
- Industry
- TOPP
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- AKTX Health Care
- Exchange
- TOPP NYSE
- AKTX Nasdaq
- Market Cap
- TOPP 26.6M
- AKTX 41.8M
- IPO Year
- TOPP 2025
- AKTX N/A
- Fundamental
- Price
- TOPP $1.79
- AKTX $1.23
- Analyst Decision
- TOPP
- AKTX
- Analyst Count
- TOPP 0
- AKTX 0
- Target Price
- TOPP N/A
- AKTX N/A
- AVG Volume (30 Days)
- TOPP 31.1K
- AKTX 11.9K
- Earning Date
- TOPP 05-15-2025
- AKTX 05-15-2025
- Dividend Yield
- TOPP N/A
- AKTX N/A
- EPS Growth
- TOPP N/A
- AKTX N/A
- EPS
- TOPP N/A
- AKTX N/A
- Revenue
- TOPP $16,117,227.00
- AKTX N/A
- Revenue This Year
- TOPP N/A
- AKTX N/A
- Revenue Next Year
- TOPP N/A
- AKTX N/A
- P/E Ratio
- TOPP N/A
- AKTX N/A
- Revenue Growth
- TOPP 0.44
- AKTX N/A
- 52 Week Low
- TOPP $0.97
- AKTX $0.85
- 52 Week High
- TOPP $4.50
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- AKTX 43.93
- Support Level
- TOPP N/A
- AKTX $1.20
- Resistance Level
- TOPP N/A
- AKTX $1.42
- Average True Range (ATR)
- TOPP 0.00
- AKTX 0.08
- MACD
- TOPP 0.00
- AKTX -0.01
- Stochastic Oscillator
- TOPP 0.00
- AKTX 14.16
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.